This company has been acquired
AGTC Aperçu des actions
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases.
| Score flocon de neige | |
|---|---|
| Évaluation | 0/6 |
| Croissance future | 2/6 |
| Performances passées | 0/6 |
| Santé financière | 3/6 |
| Dividendes | 0/6 |
Applied Genetic Technologies Corporation Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$0.39 |
| Plus haut sur 52 semaines | US$2.83 |
| Plus bas sur 52 semaines | US$0.23 |
| Bêta | 1.58 |
| 1Variation sur 1 mois | -4.23% |
| Variation sur 3 mois | -1.85% |
| Variation sur 1 an | -80.89% |
| 3Variation sur 3 ans | -86.79% |
| Variation sur 5 ans | -89.78% |
| Évolution depuis l'introduction en bourse | -97.33% |
Nouvelles et mises à jour récentes
Recent updates
AGTC receives positive feedback from FDA for manufacturing facility
Jul 26Applied Genetic Technologies proposes stock offering to fund clinical trials
Jul 12Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022
Jan 12An Assessment Of Applied Genetic Technologies Corporation
Dec 14Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk
Jul 15Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?
May 21
Applied Genetic trades lower after announcing the departure of chief scientific officer
Apr 26What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?
Feb 05
Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?
Jan 06What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Dec 11Interim data on gene therapy for vision loss disorder fails to lift Applied Genetic
Nov 11Rendement pour les actionnaires
| AGTC | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 4.8% | 0.6% | 0.3% |
| 1Y | -80.9% | 27.8% | 38.3% |
Rendement vs Industrie: AGTC underperformed the US Biotechs industry which returned -10.2% over the past year.
Rendement vs marché: AGTC underperformed the US Market which returned -14.8% over the past year.
Volatilité des prix
| AGTC volatility | |
|---|---|
| AGTC Average Weekly Movement | 19.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Cours de l'action stable: AGTC's share price has been volatile over the past 3 months.
Volatilité au fil du temps: AGTC's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1999 | 102 | Sue Washer | agtc.com |
Applied Genetic Technologies Corporation Résumé des fondamentaux
| AGTC statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$12.62m |
| Bénéfices(TTM) | -US$70.23m |
| Recettes(TTM) | US$325.00k |
38.9x
Ratio P/S-0.2x
Ratio P/ELe site AGTC est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| AGTC compte de résultat (TTM) | |
|---|---|
| Recettes | US$325.00k |
| Coût des recettes | US$21.76m |
| Marge brute | -US$21.44m |
| Autres dépenses | US$48.80m |
| Les revenus | -US$70.23m |
Derniers bénéfices déclarés
Sep 30, 2022
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -2.19 |
| Marge brute | -6,596.62% |
| Marge bénéficiaire nette | -21,610.46% |
| Ratio dettes/capitaux propres | 92.6% |
Quelles ont été les performances à long terme de AGTC?
Voir les performances historiques et les comparaisons